NSAIDs Can Be Used in the Elderly, But Only With Extreme Caution and Strict Risk Stratification
NSAIDs should be prescribed to elderly patients only after acetaminophen has failed, at the lowest effective dose, for the shortest possible duration, and with mandatory gastroprotection—while avoiding them entirely in those aged ≥75 years or with significant cardiovascular/renal disease. 1
Risk Assessment Framework
Before prescribing any NSAID to an elderly patient, you must evaluate:
Gastrointestinal Risk Factors:
- History of peptic ulcer disease or GI bleeding
- Concurrent use of low-dose aspirin, corticosteroids, or anticoagulants
- Age ≥65 years (risk increases with each decade)
- Untreated H. pylori infection 1, 2
Cardiovascular Risk Factors:
Renal Risk Factors:
- Low creatinine clearance
- Chronic kidney disease
- Intravascular depletion states
- Concurrent nephrotoxic drugs 1
The Evidence on Risk
The data are sobering: NSAIDs were implicated in 23.5% of hospitalizations due to adverse drug reactions in older adults 1. In patients >80 years, the risk increases dramatically—2-fold for GI events, 10-fold for renal events, and 7-fold for acute myocardial infarction compared to younger patients 4.
Treatment Algorithm
Step 1: First-Line Therapy (Always Start Here)
- Acetaminophen up to 3-4 g/day (consider limiting chronic use to ≤3 g/day due to hepatotoxicity concerns) 1, 5
- This is safer than NSAIDs despite concerns about liver toxicity
- Educate patients about total acetaminophen from all sources
Step 2: If Acetaminophen Fails
For patients aged 65-74 years:
- Consider topical NSAIDs (diclofenac gel) for localized joint pain—these provide similar efficacy with minimal systemic absorption and adverse effects comparable to placebo 1, 6, 7
- If oral NSAIDs are necessary:
For patients aged ≥75 years:
- Strongly prefer topical NSAIDs over oral formulations 3
- Oral NSAIDs should be avoided due to dramatically increased risk of renal and cardiovascular events 4, 9
Step 3: Absolute Contraindications
Do NOT prescribe oral NSAIDs if the patient has:
- Active peptic ulcer disease or recent GI bleeding
- Severe heart failure (NYHA Class III-IV)
- Severe renal impairment (CrCl <30 mL/min)
- Recent cardiovascular event
- Concurrent use of anticoagulants without gastroprotection 1, 10
Critical Prescribing Details
Gastroprotection Strategy:
When oral NSAIDs are unavoidable, always co-prescribe a proton pump inhibitor—this is non-negotiable in elderly patients 1, 8, 2. The combination of a COX-2 inhibitor plus PPI or non-selective NSAID plus PPI provides similar protection, though celecoxib may be preferred 2, 3.
Special Considerations:
- If patient takes low-dose aspirin for cardioprotection: The GI bleeding risk is substantially increased. Use COX-2 inhibitor plus PPI, or avoid NSAIDs entirely and consider alternative analgesics 1, 5
- Nonacetylated NSAIDs (salsalate): May have lower GI toxicity but protection is not guaranteed 1
- Drug interactions: NSAIDs increase risk when combined with ACE inhibitors, ARBs, diuretics, or anticoagulants 10, 11
Monitoring Requirements
If NSAIDs are prescribed:
- Renal function (creatinine, BUN) at baseline and periodically
- Blood pressure monitoring
- Assess for signs of GI bleeding (melena, hematemesis, anemia)
- Re-evaluate need for continuation at each visit—do not allow chronic, indefinite use 1, 3
The Bottom Line
The 2019 AGS Beers Criteria explicitly warns against chronic NSAID use in older adults due to increased risk of GI bleeding, cardiovascular events, and renal toxicity 10. Multiple international guidelines (EULAR, NICE, ESCEO, OARSI) consistently recommend NSAIDs only as second-line therapy after non-pharmacological measures and acetaminophen have failed, with mandatory risk stratification 8, 2, 3, 6.
In patients ≥80 years, the absolute risk becomes so high that NSAIDs should be considered a last resort, reserved only for situations where pain is severely impacting quality of life and all other options have been exhausted 4, 9. Even then, topical formulations should be strongly preferred over oral agents 3, 6, 7.